Nova Eye Medical (EYE) Discussion, page-1090

Yeah, which is why I'm happy to make a punt that the LCD won't be implemented, and that if it is implemented, we will not have much difficulty appealing it. I feel that between the low probability of implementation, and the high probability of a successful appeals process, that the overall probability of the LCD impacting anything more than sentiment is quite low, and that even if it does go ahead, our price is so low relative to the net asset value and revenue that the downside risk is quite limited (compared to PEB).

On the other hand, the upside from an announcement stating that the LCD has been revised or completely retired should be quite substantial at this current price. This appears to me to be a high probability scenario, so I'm expecting this to be a nearer term rerate catalyst than the release of earnings.